Abstract
About 30 % of phaeochromocytomas or paragangliomas are genetic. Whilst some individuals will have clinical features or a family history of inherited cancer syndrome such as neurofibromatosis type 1 (NF1) or multiple endocrine neoplasia 2 (MEN2), the majority will present as an isolated case. To date, 14 genes have been described in which pathogenic mutations have been demonstrated to cause paraganglioma or phaeochromocytoma . Many cases with a pathogenic mutation may be at risk of developing further tumours. Therefore, identification of genetic cases is important in the long-term management of these individuals, ensuring that they are entered into a surveillance programme. Mutation testing also facilitates cascade testing within the family, allowing identification of other at-risk individuals. Many algorithms have been described to facilitate cost-effective genetic testing sequentially of these genes, with phenotypically driven pathways. New genetic technologies including next-generation sequencing and whole-exome sequencing will allow much quicker, cheaper and extensive testing of individuals in whom a genetic aetiology is suspected.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Alam NA et al (2003) Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency. Hum Mol Genet 12(11):1241–1252. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12761039
Astuti D et al (2001) Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 69(1):49–54. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1226047&tool=pmcentrez&rendertype=abstract
Astuti D et al (2011) Mutation analysis of HIF prolyl hydroxylases (PHD/EGLN) in individuals with features of phaeochromocytoma and renal cell carcinoma susceptibility. Endocr Relat Cancer 18(1):73–83. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3006001&tool=pmcentrez&rendertype=abstract
Bamshad MJ et al (2011) Exome sequencing as a tool for Mendelian disease gene discovery. Nat Rev Genet 12(11):745–755. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21946919
Bausch B, Borozdin W, Neumann HPH (2006) Clinical and genetic characteristics of patients with neurofibromatosis type 1 and pheochromocytoma. N Engl J Med 354(25):2729–2731. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16790714
Bayley J-P et al (2010) SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma. Lancet Oncol 11(4):366–372. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20071235
Bayley J-P et al (2014) Paraganglioma and pheochromocytoma upon maternal transmission of SDHD mutations. BMC Med Genet 15:111. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4259087&tool=pmcentrez&rendertype=abstract
Baysal BE et al (2000) Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 287(5454):848–851. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10657297
Benn DE et al (2006) Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab 91(3):827–836. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16317055
Boedeker CC et al (2009) Head and neck paragangliomas in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 94(6):1938–1944. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2690424&tool=pmcentrez&rendertype=abstract
Brito JP et al (2014) Testing for germline mutations in sporadic pheochromocytoma/paraganglioma: a systematic review. Clin Endocrinol 1–8
Brouwers FM et al (2006) High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J Clin Endocrinol Metab 91(11):4505–4509. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16912137
Buffet A et al (2012) A decade (2001–2010) of genetic testing for pheochromocytoma and paraganglioma. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 44(5):359–366. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22517557
Burnichon N et al (2012a) The genetics of paragangliomas. Eur Ann Otorhinolaryngol Head Neck Dis 129(6):315–318. Available at: http://www.sciencedirect.com/science/article/pii/S1879729612000816
Burnichon N et al (2012b) MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clin Cancer Res (official journal of the American Association for Cancer Research) 18(10):2828–2837. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22452945
Burnichon N et al (2010) SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet 19(15):3011–3020. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2901140&tool=pmcentrez&rendertype=abstract
Carney JA, Stratakis CA (2002) Familial paraganglioma and gastric stromal sarcoma: a new syndrome distinct from the Carney triad. Am J Med Genet 108(2):132–139. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11857563
Cascón A et al (2015) Whole-exome sequencing identifies MDH2 as a new familial paraganglioma gene. J Natl Cancer Inst 107(5). Available at: http://www.ncbi.nlm.nih.gov/pubmed/25766404
Castro-Vega LJ et al (2014) Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas. Hum Mol Genet 23(9):2440–2446. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24334767
Chen H et al (2010) The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas 39(6):775–783
Clark GR et al (2014) Germline FH mutations presenting with pheochromocytoma. J Clin Endocrinol Metab 99(10):E2046–E2050. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25004247
Comino-Méndez I et al (2011) Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet 43(7):663–667. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21685915
Därr R et al (2012) Pheochromocytoma—update on disease management. Ther Adv Endocrinol Metab 3(1):11–26. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3474647&tool=pmcentrez&rendertype=abstract
Dwight T et al (2013) Familial SDHA mutation associated with pituitary adenoma and pheochromocytoma/paraganglioma. J Clin Endocrinol Metab 98(6):E1103–E1108. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23633203
Elston MS et al (2013) Novel mutation in the TMEM127 gene associated with phaeochromocytoma. Int Med J 43(4):449–451. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23551308
Fallon SC et al (2013) The utility of cortical-sparing adrenalectomy in pheochromocytomas associated with genetic syndromes. J Pediatr Surg 48(6):1422–1425. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23845641
Ferner RE et al (2007) Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet 44(2):81–88. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2598063&tool=pmcentrez&rendertype=abstract
Frank-Raue K et al (2011) Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10. Hum Mutat 32(1):51–58. Available at: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=20979234
Gaal J et al (2009) Parasympathetic paragangliomas are part of the Von Hippel-Lindau syndrome. J Clin Endocrinol Metab 94(11):4367–471. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19808854
Gill AJ et al (2014) Succinate dehydrogenase (SDH)-deficient renal carcinoma: a morphologically distinct entity: a clinicopathologic series of 36 tumors from 27 patients. Am J Surg patholo 38(12):1588–1602. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4229399&tool=pmcentrez&rendertype=abstract
Gimenez-Roqueplo A-P et al (2003) Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res 63(17):5615–5621. Available at: http://www.ncbi.nlm.nih.gov/pubmed/14500403
Giovannoni I et al (2014) Malignant pheochromocytoma in a 16-year-old patient with neurofibromatosis type 1. Pediatric and developmental pathology (the official journal of the Society for Pediatric Pathology and the Paediatric Pathology) Society 17(2):126–129. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24555864
Grubbs EG et al (2013) Long-term outcomes of surgical treatment for hereditary pheochromocytoma. J Am Coll Surg 216(2):280–289. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23317575
Hao H-X et al (2009) SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science 325(5944):1139–1142. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3881419&tool=pmcentrez&rendertype=abstract
Heesterman BL et al (2012) High prevalence of occult paragangliomas in asymptomatic carriers of SDHD and SDHB gene mutations. Euro J Hum Genet 21(4):469–470. Available at: http://dx.doi.org/10.1038/ejhg.2012.203
Hernandez KG et al (2015) Familial pheochromocytoma and renal cell carcinoma syndrome: TMEM127 as a novel candidate gene for the association. Virchows Arch : Int J Pathol. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25800244
Hes F et al (2000) Genotype-phenotype correlations in families with deletions in the von Hippel-Lindau (VHL) gene. Hum Gene 106(4):425–431. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10830910
Hes FJ, Höppener JWM, Lips CJM (2003) Clinical review 155: Pheochromocytoma in Von Hippel-Lindau disease. J Clin Endocrinol Metab 88(3):969–974. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12629069
Hes FJ et al (2010) Low penetrance of a SDHB mutation in a large Dutch paraganglioma family. BMC Med Genet 11(1):92. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2891715&tool=pmcentrez&rendertype=abstract
Jafri M, Maher ER (2012) The genetics of phaeochromocytoma: using clinical features to guide genetic testing. Euro J Endocrinol Euro Fed Endocr Soc 166(2):151–158. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21896620
Jafri M et al (2013) Evaluation of SDHB, SDHD and VHL gene susceptibility testing in the assessment of individuals with non-syndromic phaeochromocytoma, paraganglioma and head and neck paraganglioma. Clin Endocrinol 78(6):898–906. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23072324
Karasek D et al (2013) An update on the genetics of pheochromocytoma. J Hum Hypertens 27(3):141–147. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4060418&tool=pmcentrez&rendertype=abstract
Kloos R et al (2009) Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19(6). Available at: http://online.liebertpub.com/doi/abs/10.1089/thy.2008.0403
Korpershoek E et al (2011) SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas. J Clin Endocrinol Metab 96(9):E1472–E1476. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21752896
Krampitz GW, Norton JA (2014) RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma. Cancer 120(13):1920–1931. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24699901
Kunst HPM et al (2011) SDHAF2 (PGL2-SDH5) and hereditary head and neck paraganglioma. Clin Cancer Res (an official journal of the American Association for Cancer Research) 17(2):247–254. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21224366
Lack EE et al (2003) Recommendations for the reporting of extra-adrenal paragangliomas. The Association of Directors of Anatomic and Surgical Pathology. Hum Pathol 34(2):112–113. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12612877
Ladroue C et al (2008) PHD2 mutation and congenital erythrocytosis with paraganglioma. N Engl J Med 359(25):2685–2692. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19092153
Lee S et al (2005) Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell 8(2):155–167. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16098468
Lenders JWM et al (2014) Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(6):1915–1942. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24893135
Lips CJM et al (2006). Familial paragangliomas. Hered Cancer Clin Pract, 4(4):169–176. Available at: http://openi.nlm.nih.gov/detailedresult.php?img=2837305_1897-4287-4-4-169-1&req=4
Lorenzo FR et al (2013) A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma. J Mol Med 91(4):507–512. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3570726&tool=pmcentrez&rendertype=abstract
Maher ER et al (1996) Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations. J Med Genet 33(4):328–332. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1050584&tool=pmcentrez&rendertype=abstract
Maher ER, Neumann HP, Richard S (2011) von Hippel-Lindau disease: a clinical and scientific review. Euro J Hum Gene: EJHG 19(6):617–623. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3110036&tool=pmcentrez&rendertype=abstract
Manger WM (2009) The protean manifestations of pheochromocytoma. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 41(9):658–663. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19242899
Mannelli M et al (2009) Clinically guided genetic screening in a large cohort of Italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas. J Clin Endocrinol Metab 94(5):1541–1547
Martins R, Bugalho MJ (2014) Paragangliomas/pheochromocytomas: clinically oriented genetic testing. Int J Endocrinol 2014:794187. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4037125&tool=pmcentrez&rendertype=abstract
Martucci VL, Pacak K (2014) Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment. Curr Prob Cancer 38(1):7–41. Available at: http://dx.doi.org/10.1016/j.currproblcancer.2014.01.001
McGaughran JM et al (1999) A clinical study of type 1 neurofibromatosis in north west England. J Med Genet 36(3):197–203. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1734324&tool=pmcentrez&rendertype=abstract
Moline J, Eng C (2011) Multiple endocrine neoplasia type 2: an overview. Genet Med (official journal of the American College of Medical Genetics) 13(9):755–764. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21552134
Myssiorek D et al (2008) Screening for familial paragangliomas. Oral Oncol 44(6):532–537. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17936061
Neumann Hartmut PHB (2002) Germ-line mutations in nonsyndromic pheochromocytoma. N Eng J Med 347(11):854–855; author reply 854–855
Neumann HPH et al (2011) Germline mutations of the TMEM127 gene in patients with paraganglioma of head and neck and extraadrenal abdominal sites. J Clin Endocrinol Metab 96(8):E1279–E1282. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21613359
Niemann S, Müller U (2000) Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet 26(3):268–270. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11062460
Ong KR et al (2007) Genotype-phenotype correlations in von Hippel-Lindau disease. Hum Mutat 28(2):143–149. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17024664
Pacak K, Eisenhofer G, Ilias I (2009) Diagnosis of pheochromocytoma with special emphasis on MEN2 syndrome. Hormones 8:111–116
Papaspyrou K, Mann WJ, Amedee RG (2009) Management of head and neck paragangliomas: review of 120 patients. Head Neck 31(3):381–387. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18972432
Pasini B et al (2008) Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Euro J Hum Genet: EJHG 16(1):79–88. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17667967
Persky MJ et al (2015) The necessity for lifelong follow up of patients with familial paraganglioma syndrome—a case report. Head Neck. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25783443
Ponder BA et al (1988) Risk estimation and screening in families of patients with medullary thyroid carcinoma. Lancet 1(8582):397–401. Available at: http://www.ncbi.nlm.nih.gov/pubmed/2893198
Qin Y et al (2010) Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nat Genet 42(3):229–233. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2998199&tool=pmcentrez&rendertype=abstract
Rattenberry E et al (2013) A comprehensive next generation sequencing-based genetic testing strategy to improve diagnosis of inherited pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 98(7):E1248–E1256. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23666964
Rauen KA et al (2015) Recent developments in neurofibromatoses and RASopathies: management, diagnosis and current and future therapeutic avenues. Am J Med Genet. Part A 167A(1):1–10. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25393061
Raygada M et al (2014) Counseling patients with succinate dehydrogenase subunit defects: genetics, preventive guidelines, and dealing with uncertainty. J Pediatr Endocrinol Metab: JPEM 27(9–10):837–844. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24854530
Riccardi VM (1981) Von Recklinghausen neurofibromatosis. N Eng J Med 305(27):1617–1627. Available at: http://www.ncbi.nlm.nih.gov/pubmed/6796886
Ricketts C et al (2008) Germline SDHB mutations and familial renal cell carcinoma. J Nat Cancer Inst 100(17):1260–1262. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18728283
Ricketts CJ et al (2010) Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD. Hum Mutat 31(1):41–51. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19802898
Robson ME et al (2010) American society of clinical oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol : official journal of the American Society of Clinical Oncology 28(5):893–901. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20065170
Rodriguez JM et al (2008) Pheochromocytoma in MEN 2A syndrome. Study of 54 patients. World J Surg 32(11):2520–2526. Available at: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med5&NEWS=N&AN=18795243
Sahdev A et al (2005) CT and MR imaging of unusual locations of extra-adrenal paragangliomas (pheochromocytomas). Euro Radiol 15(1):85–92. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15290072
Schiavi F et al (2005) Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. JAMA 294(16):2057–2063. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16249420
Schlisio S et al (2008) The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev 22(7):884–893. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2279200&tool=pmcentrez&rendertype=abstract
Schmid S et al (2014) Management of von hippel-lindau disease: an interdisciplinary review. Oncol Res Treat 37(12):761–71. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25531723
Shepet K et al (2013) Hereditary medullary thyroid cancer: age-appropriate thyroidectomy improves disease-free survival. Ann Surg Oncol 20(5):1451–1455. Available at: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=23188542
Taïeb D et al. (2013) First report of bilateral pheochromocytoma in the clinical spectrum of HIF2A-related polycythemia-paraganglioma syndrome. J Clin Endocrinol Metab 98(5):E908–E913. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3644612&tool=pmcentrez&rendertype=abstract
Timmers HJLM et al (2007) Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas. J Clin Endocrinol Metab 92(3):779–786. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17200167
Toledo RA, Dahia PLM (2015) Next-generation sequencing for the diagnosis of hereditary pheochromocytoma and paraganglioma syndromes. Curr Opin Endocrinol Diab Obes 22(3):169–179. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25871962
Toledo SPA et al (2015) Penetrance and clinical features of pheochromocytoma in a six-generation family carrying a germline TMEM127 mutation. J Clin Endocrinol Metab 100(2):E308–E318. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25389632
Van Hulsteijn LT et al (2012) Risk of malignant paraganglioma in SDHB-mutation and SDHD-mutation carriers: a systematic review and meta-analysis. J Med Genet 49(12):768–776. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23099648
Van Hulsteijn LT et al (2013) No difference in phenotype of the main Dutch SDHD founder mutations. Clin Endocrinol 79(6):824–31. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23586964
Van Hulsteijn LT et al (2015) No evidence for increased mortality in SDHD variant carriers compared with the general population. Euro J Hum Genet: EJHG. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25758995
Waguespack SG et al (2011) Management of medullary thyroid carcinoma and MEN2 syndromes in childhood. Nat Rev Endocrinol 7(10):596–607. Available at: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=21862994
Yang C et al (2015) Germ-line PHD1 and PHD2 mutations detected in patients with pheochromocytoma/paraganglioma-polycythemia. J Mole Med 93(1):93–104. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25263965
Yao L et al (2010) Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas. JAMA 304(23):2611–2619
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Lalloo, F. (2016). Diagnosis and Management of Hereditary Phaeochromocytoma and Paraganglioma. In: Pichert, G., Jacobs, C. (eds) Rare Hereditary Cancers. Recent Results in Cancer Research, vol 205. Springer, Cham. https://doi.org/10.1007/978-3-319-29998-3_7
Download citation
DOI: https://doi.org/10.1007/978-3-319-29998-3_7
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-29996-9
Online ISBN: 978-3-319-29998-3
eBook Packages: MedicineMedicine (R0)